TY - JOUR
T1 - Diagnostic laboratory immunology for talaromycosis (penicilliosis)
T2 - review from the bench-top techniques to the point-of-care testing
AU - Pruksaphon, Kritsada
AU - Intaramat, Akarin
AU - Ratanabanangkoon, Kavi
AU - Nosanchuk, Joshua D.
AU - Vanittanakom, Nongnuch
AU - Youngchim, Sirida
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/3
Y1 - 2020/3
N2 - The pathogenic fungus Talaromyces (formerly Penicillium) marneffei is a thermally dimorphic fungus that can cause disseminated infection in patients with secondary immunodeficiency syndrome, in particular in the setting of advanced HIV infection. The areas of highest incidence are in Southeast Asia, Southern China, and Indian subcontinents. Talaromycosis (formerly penicilliosis) is identified as an AIDS-defining illness, and it has recently been recognized in non–HIV-associated patients with impaired cellular-mediated immunity. Microbiological culture is the gold standard method for the diagnosis of T. marneffei infection and usually requires up to 2–4 weeks for detectable growth to occur, which may result in a delay of appropriate treatment. Immunodiagnosis has become an alternative method for confirming talaromycosis. This article reviews various immunological tests for the diagnosis of talaromycosis, including a proposed novel rapid point-of-care assay using a new T. marneffei yeast phase-specific monoclonal antibody.
AB - The pathogenic fungus Talaromyces (formerly Penicillium) marneffei is a thermally dimorphic fungus that can cause disseminated infection in patients with secondary immunodeficiency syndrome, in particular in the setting of advanced HIV infection. The areas of highest incidence are in Southeast Asia, Southern China, and Indian subcontinents. Talaromycosis (formerly penicilliosis) is identified as an AIDS-defining illness, and it has recently been recognized in non–HIV-associated patients with impaired cellular-mediated immunity. Microbiological culture is the gold standard method for the diagnosis of T. marneffei infection and usually requires up to 2–4 weeks for detectable growth to occur, which may result in a delay of appropriate treatment. Immunodiagnosis has become an alternative method for confirming talaromycosis. This article reviews various immunological tests for the diagnosis of talaromycosis, including a proposed novel rapid point-of-care assay using a new T. marneffei yeast phase-specific monoclonal antibody.
KW - Immunochromatography
KW - Immunodiagnosis
KW - Monoclonal antibody
KW - Talaromyces (Penicillium) marneffei
KW - Talaromycosis (penicilliosis) marneffei
UR - http://www.scopus.com/inward/record.url?scp=85076547589&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076547589&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2019.114959
DO - 10.1016/j.diagmicrobio.2019.114959
M3 - Review article
C2 - 31836254
AN - SCOPUS:85076547589
SN - 0732-8893
VL - 96
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 3
M1 - 114959
ER -